ArticleTranslational neuroscience2026
A Two-way Mendelian randomisation study of inflammatory factors and the risk of meningioma.
Article in Translational neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the causal relationship between inflammatory factors and meningioma. Methods: The inverse variance weighting method (IVW), Mendelian Randomisation Egger (MR-Egger) regression, weighted median method, simple mode method, and weighted mode method were used to analyse the potential causal relationship between exposure factors and outcomes. Results: Preliminary MR analysis showed that 6 inflammatory factors, including C-C motif chemokine 19 levels, osteoprotegerin levels, Fms-related tyrosine kinase 3 (FLT3) ligand levels, matrix metalloproteinase-1 levels, C-C motif chemokine 28 levels, and interleukin-5 levels, were associated with meningiomas. Further screening of inflammatory factors and positive MR analysis showed that FLT3 ligand levels had a clear causal association with the occurrence of meningioma (odds ratio [OR]=0.713, 95 % confidence interval [CI]: 0.598-0.851). The results of reverse MR analysis showed that there was a clear causal association between meningioma and Fms-related tyrosine kinase 3 ligand levels (OR=0.936, 95 % CI: 0.885-0.990). The results of heterogeneity and pleiotropic tests of MR-Egger intercept showed that there was no heterogeneity or pleiotropy in all data. Conclusions: This study clarified FLT3 as being involved in the pathogenesis of meningioma from a genetic perspective and genetically predicted lower FLT3L to be causally associated with a higher meningioma risk, implicating FLT3 signalling in meningioma pathogenesis. FLT3 as a genetically supported candidate factor associated with meningioma risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.